← Back to patent-cliff list
6-[18F]Fluorodopa
Tier C — Watch / trade6-[18F]Fluorodopa
Novartis
Originator
2016
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Brand：IASOdopa
Indications (approved)：Parkinsonism, Diagnostic agent
Regional status
US
Approved
2019-10-10
EU
Approved
2016-11-01
China
Phase III
2024-11-15
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 6-[18F]Fluorodopa?
Approved indications include: Parkinsonism, Diagnostic agent.
When does the 6-[18F]Fluorodopa patent expire?
No public expiry year is available for 6-[18F]Fluorodopa yet; this page updates once verified.
How do I get a quote for 6-[18F]Fluorodopa intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29